adaptive study designs
TRANSCRIPT
Adaptive Study Designs
Dr. Anirudha Potey
1
Background
2
Defining adaptive study design
Guidance for Industry: Adaptive Design Clinical Trials for Drugs and Biologics
‘a study that includes a prospectively planned opportunity for modification of one or more specified aspects of the study design and hypotheses based on analysis of data (usually interim data) from subjects in the study ’
3
without undermining the validity and integrity of
the trial
Is Adaptive Study Design a Modern Phenomenon?
4
Not Adaptive Study Design
Revisions based on the data
• Obtained external of the current trial
• After unblinding data and not pre-planned
5
Types of adaptations
• Prospective
• Concurrent
• Retrospective
6
Types of adaptations
Trial procedures
Eligibility criteria
Study dose – therapy regimen
Duration of treatment
Study endpoints
Lab testing procedures
Diagnostic procedures
Concomitant treatments used
7
Types of adaptations
Trial procedures
Planned schedule of the patient evaluations
evaluations for the data collection (eg.
number of the intermediate time points,
timing of the last patient observation and
duration of the patient study participation)
Criteria for evaluation and assessment of
clinical responses
8
Types of adaptations
9
Statistical procedure
Randomization
Study design
Study hypothesis
Sample size
Data monitoring
Interim analysis
Statistical analysis plan/
Well understood Adaptive Study Designs
• Adaptation of Study Eligibility Criteria Based
• Adaptations to Maintain Study Power
• Adaptations based on the interim results of an outcome unrelated to efficacy
10
Well understood Adaptive Study Designs
• Adaptations Using Group Sequential Methods and unblinded Analyses
• Adaptations based on the Data Analysis Plan
• Adaptation for the primary endpoint
11
Types of Adaptive Study Designs• Adaptive Randomization Design
• Sample size re-estimation design
• Drop the loser design
• Adaptive dose finding design
• Biomarker adaptive design
• Adaptive treatment switching design
• Group sequential design
• Hypothesis adaptive design
• Adaptive seamless phase II/III trial design
• Multiple adaptive design12
Allocation
rule
Sampling
rule
Stopping
rule
Decision
rule
Fifth rule
Adaptive Randomization
13
Group Sequential Design
14
Group Sequential Design
• Early Termination
• Stopping rules
• Utility rules
• Futility rules
15
Sample size re-estimation
16
Drop the loser
17
Adaptive Dose finding design
18
Biomarker adaptive design
19
Adaptive treatment switching design
20
Hypothesis adaptive design
21
Adaptive seamless phase II/III design
22
Multiple adaptive designs
23
Advantages over Conventional Study Designs• Same information more efficiently
• More success
• Improved understanding of treatment effect
• CSD – inaccurate estimates or assumptions
• Decrease cost and time by discontinuing a group
• Adjust sample to avoid an undesired powered study
• Assessment of more choices within same time frame
• No protocol amendment24
Comparing Adaptive and Conventional study designsFeatures Conventional
trial
Adaptive design
Design More rigid Flexible
Treatment arms Max. 2 – 3 Many
simultaneously
Hypothesis Test the
hypothesis
under
consideration
Fit data into
hypothesis
Modifications Not allowed
without protocol
amendments
Pre-specified
allowed25
Comparing Adaptive and Conventional study designs
Features Conventional
trial
Adaptive design
Phases Phases I – II are
well defined
Can be seamless
phase 2/3
Statistical
analysis
Frequentist
approach
Complicated
Bayesian
approach
Organization Much simple Complicated
Interim analysis Not routine Routinely and
frequently
Regulatory view Well endorsed speculative26
Concerns associated with Adaptive study designs
• Increased type I error
• Difficult interpretation of results
• More planning and lead time
• Develop into a completely different trial
• Incorporation of a totally different population
• Bayesian statistics
• Computer based simulations
• Challenge to CROs and EC27
Concerns associated with Adaptive study designs
• Lack of definition by regulatory authorities
• Bayesian approach is compulsion – non
standard
• Damage to integrity
• Magnify bias with increase in sample size
28
Procedural issues
• Rapid electronic collection of data
• Efficient interaction b/w investigator and
sponsor
• Financial investments
• Computer based simulations with
infrastructure and software
• CRO & EC lack experience of monitoring
29
Regulatory perspective
• Acceptable level of adaptation?
• Regulatory standards for review and approval
process of clinical data?
• A completely new clinical trial post
modification?
• Increased interaction b/w FDA and sponsors
30
Ethics
31
Writing adaptive protocols
• Description of adaptive features
• Defining limits of adaptations
• Description of control mechanism
32
Keep in mind the adaptive process
33
Conclusion
• Many advantages
• Infant stage – many areas are controversial
• Not an ad hoc measure for poor planning
• Strong promise for the future
• More guidelines and better understanding
• Complexities limit use
34
35